These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38590780)

  • 1. Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001-2020.
    Wei Y; Zhang Y; Xu Z; Wang G; Zhou Y; Li H; Shi L; Naci H; Wagner AK; Guan X
    Lancet Reg Health West Pac; 2024 Apr; 45():101055. PubMed ID: 38590780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.
    Michaeli DT; Mills M; Michaeli T; Miracolo A; Kanavos P
    Invest New Drugs; 2022 Aug; 40(4):798-809. PubMed ID: 35389145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential times of submission and approval of CFTR modulators for the treatment of Cystic Fibrosis in the United States and the European Union.
    Costa E; Girotti S; Mathieu C; Castellani C; Ross JS; Taylor-Cousar JL; Leufkens HGM
    J Cyst Fibros; 2024 Aug; ():. PubMed ID: 39183127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia.
    Hwang TJ; Kesselheim AS; Tibau A; Lee CC; Vokinger KN
    JCO Oncol Pract; 2022 Sep; 18(9):e1522-e1532. PubMed ID: 35731996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval.
    Gyawali B; Hey SP; Kesselheim AS
    JAMA Intern Med; 2019 Jul; 179(7):906-913. PubMed ID: 31135808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Childhood cancer drugs in China: An overview and comparison of regulatory approvals in China and the United States.
    Zhang Y; Katharina Wagner A; Du H; Han T; Gupta S; Denburg AE; Frazier AL; Guan X; Shi L
    Int J Cancer; 2022 Feb; 150(3):482-490. PubMed ID: 34536294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The regulatory approvals of immune checkpoint inhibitors in China and the United States: A cross-national comparison study.
    Jin Y; Li H; Zhang P; Yu M; Zhang H; Li X
    Int J Cancer; 2023 Jun; 152(11):2351-2361. PubMed ID: 36632000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020.
    Zhang Y; Naci H; Wagner AK; Xu Z; Yang Y; Zhu J; Ji J; Shi L; Guan X
    JAMA Netw Open; 2022 Aug; 5(8):e2225973. PubMed ID: 35947385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
    Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
    Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis.
    Ivama-Brummell AM; Marciniuk FL; Wagner AK; Osorio-de-Castro CGS; Vogler S; Mossialos E; Tavares-de-Andrade CL; Naci H
    Lancet Reg Health Am; 2023 Jun; 22():100506. PubMed ID: 37235087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021.
    Michaeli DT; Michaeli T
    J Clin Oncol; 2022 Dec; 40(35):4095-4106. PubMed ID: 35921606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations.
    Ghadanian M; Schafheutle E
    Ther Innov Regul Sci; 2024 Jan; 58(1):79-113. PubMed ID: 37861859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the Delay in Novel Anticancer Drugs between China and the United States: A Comparative Study of Drugs Approved between 2010 and 2021.
    Luo X; Du X; Li Z; Qian F; Yang Y
    Clin Pharmacol Ther; 2023 Jan; 113(1):170-181. PubMed ID: 36151921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.
    Dhodapkar M; Zhang AD; Puthumana J; Downing NS; Shah ND; Ross JS
    JAMA Netw Open; 2021 Jun; 4(6):e2113224. PubMed ID: 34110392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A New Look At United States Drug Development and Approval Times.
    DiMasi JA
    Am J Ther; 1996 Sep; 3(9):647-657. PubMed ID: 11862306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.
    Davis C; Naci H; Gurpinar E; Poplavska E; Pinto A; Aggarwal A
    BMJ; 2017 Oct; 359():j4530. PubMed ID: 28978555
    [No Abstract]   [Full Text] [Related]  

  • 19. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
    Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
    Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.